American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Warns Docs, Consumers About Unapproved IUDs

Agency Questions Safety, Efficacy of Imported Products

By News Staff

The FDA is warning physicians (2-page PDF; About PDFs) and consumers about risks associated with the use of unapproved intrauterine devices, or IUDs, and intrauterine systems, or IUSs.
FDA News
The agency said in a July 22 letter to physicians that the items in question include unapproved versions of FDA-approved products, such as Mirena (levonorgestrel IUS), Implanon (etonogestrel implant) and ParaGard (copper-T IUD), as well as products not approved for use in the United States, such as T-Safe.

Unapproved Products Raise Concerns About Safety, Effectiveness

According to the FDA, such unapproved products could be unsafe and ineffective. The agency said the products may not have been manufactured, transported or stored under the stringent conditions required by the agency.

Physicians should not insert IUD or IUS products furnished by a patient who may have purchased the product online without verifying that it is an FDA-approved product purchased from a licensed pharmaceutical or device supplier in the United States, FDA officials said.

Legitimate Internet pharmacies are licensed by state pharmacy boards and display the National Association of Boards of Pharmacy's Verified Internet Pharmacy Practice Sites, or VIPPS, seal.

The FDA also said women who think they may be using an unapproved product should employ another form of birth control. The agency advised such women to contact their physician to discuss whether the product should be removed and to talk about other birth control options.

As Costs Rise, Some Seek Less Pricey Options

In October 2009, the FDA approved Mirena to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention, making it the first IUD approved for that additional indication. According to numerous published reports, Bayer HealthCare Pharmaceuticals doubled the price of the device to more than $700 earlier this year.

Meanwhile, the product -- or unapproved versions of it -- can be found on international websites for half the price charged on the U.S. market. The FDA said medical professionals and consumers might be tempted to buy products from foreign-based websites in an attempt to save money.

However, the agency said the use of and subsequent billing for unapproved medical products raises the possibility of insurance fraud if a payer thinks it's paying for an FDA-approved product when, in fact, it's not.

The agency said it is aware of the use of unapproved products in several states, and an investigation is ongoing. The investigation started in Rhode Island, where, according to the State of Rhode Island Department of Health, 10 medical practices have purchased or used unapproved devices.

Information regarding the distribution of unapproved products can be reported anonymously to the FDA's Office of Criminal Investigations online.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing